Latest news about Lincoln Pharmaceuticals
Lincoln Pharma Q1 Results: Net profit up 31% YoY to ₹362 crore
Lincoln Pharmaceuticals
609.65
+2.90(+0.48%)
Company Performance:
View Company Insights1D+0.48%
1M+5.63%
6M-3.39%
1Y+13.18%
5Y+83.71%
More news about Lincoln Pharmaceuticals
08May 26
Lincoln Pharmaceuticals Issues Public Notice for Transfer of Equity Shares to IEPF Authority
Lincoln Pharmaceuticals Ltd published a newspaper advertisement on May 08, 2026, notifying shareholders of the impending transfer of equity shares to the IEPF Authority under Section 124(6) of the Companies Act, 2013 and Regulation 47 of SEBI (LODR) Regulations, 2015. The notice covers shares on which dividends for the financial year 2018-2019 have remained unclaimed for seven or more consecutive years. Shareholders are required to lodge their claims with the company's RTA, MUFG Intime India Private Limited, on or before 31st July, 2026 to avoid transfer of their shares to the IEPF Authority. Post-transfer, all claims must be made directly with the IEPF Authority, with details available at www.iepf.gov.in.
16Apr 26
Lincoln Pharmaceuticals Limited Confirms Non-Large Corporate Status Under SEBI Framework for FY 2026-27
Lincoln Pharmaceuticals Limited has notified stock exchanges that it does not qualify as a Large Corporate under SEBI's regulatory framework for FY 2026-27. The company submitted its mandatory disclosure on April 16, 2026, confirming that criteria such as outstanding borrowing and credit rating thresholds do not apply to its operations. The disclosure was properly executed by Company Secretary Trusha Shah and CFO Darshit Shah, demonstrating compliance with SEBI circular SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.
07Apr 26
Lincoln Pharmaceuticals Submits Q4FY26 SEBI Compliance Certificate for Dematerialisation Process
Lincoln Pharmaceuticals Limited filed its Q4FY26 confirmation certificate under SEBI Regulation 74(5) with NSE and BSE on April 06, 2026. The certificate from registrar MUFG Intime India Private Limited confirms proper processing of dematerialisation activities during the quarter ended March 31, 2026, including timely confirmation of securities, proper listing compliance, and substitution of depository names in the register of members.
23Feb 26
Lincoln Pharmaceuticals Q3 FY26 Results: Revenue Grows 13.5% to ₹166.32 Crores, Net Profit Jumps 37.7%
Lincoln Pharmaceuticals reported strong Q3 FY26 results with revenue growing 13.5% to ₹166.32 crores and net profit surging 37.7% to ₹28.60 crores. The company's Cephalosporin block achieved profitability, contributing ₹45 crores in FY26 revenue. International expansion continues with Canadian operations generating $4-5 million annually, while the company increases R&D spending to 3.0-3.25% of revenue to support its ₹1,000 crores long-term target.
18Feb 26
Lincoln Pharmaceuticals Makes Q3FY26 Conference Call Recording Available
Lincoln Pharmaceuticals has fulfilled regulatory requirements by making available the audio recording of its Q3FY26 results conference call held on February 18, 2026. This follows the company's impressive quarterly performance showing 37.70% YoY net profit growth to ₹28.60 crore and 13.49% revenue growth to ₹166.32 crore.
10Jan 26
Lincoln Pharmaceuticals Receives CRISIL Credit Rating Reaffirmation at A/Stable for Long-term Facilities
Lincoln Pharmaceuticals Limited received credit rating reaffirmation from CRISIL Limited on January 09, 2026, with long-term bank facilities maintained at CRISIL A/Stable and short-term facilities at CRISIL A1. The ratings cover total bank facilities of ₹102.00 crore and reflect the company's established market position, promoter experience, and healthy financial profile with ₹671.00 crore networth against nil debt. Revenue grew 14.00% to ₹623.23 crore in fiscal 2025, though working capital intensity and regulatory risks remain areas of concern.
07Aug 25
Lincoln Pharma Reports 17% Net Profit Growth in Q1, Targets ₹1,000 Crore Revenue in 3 Years
Lincoln Pharmaceuticals reported strong Q1 FY26 results with a 17% increase in net profit to ₹27.70 crore and a 7.3% rise in total income to ₹169.34 crore. EBITDA grew by 17.92% to ₹39.08 crore. The company aims to achieve ₹1,000 crore in revenue within three years, targeting 15-18% annual growth. Lincoln Pharma launched a bulk drug manufacturing plant and received approvals for 10 products. The company's shares closed at ₹576.90 on BSE, up 8.47%.
07Aug 25
Lincoln Pharmaceuticals Reports 16.93% Profit Growth in Q1, Reappoints Key Directors
Lincoln Pharmaceuticals reported a 16.93% year-on-year increase in Q1 net profit to Rs. 27.70 crore. Total income rose by 7.39% to Rs. 169.34 crore, while EBITDA grew 17.92% to Rs. 39.08 crore. The company re-appointed key leadership positions, including Mahendra G. Patel as Managing Director. Lincoln aims to achieve Rs. 1,000 crore revenue within three years, targeting 15-18% annual growth. The company plans to expand its global presence from 60+ to 90 countries in 2-3 years. FII stake in the company increased from 3.95% to 5.13% over the past year.
02Jul 25
Lincoln Pharmaceuticals Completes Trial Run at Khatraj Facility, Eyes API Production
Lincoln Pharmaceuticals has successfully completed the trial run of its Khatraj facility, a key step in its expansion plans. The company aims to commence commercial production of Active Pharmaceutical Ingredients (APIs) at this facility within 1-2 years, subject to regulatory approvals. This move is expected to enhance manufacturing capabilities, potentially leading to vertical integration, cost efficiency, improved quality control, and stronger market positioning.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Lupin
Dr Reddys Laboratories
Mankind Pharma
Aurobindo Pharma
1,929.00
(-2.81%)
9,165.00
(-3.19%)
4,965.50
(-1.98%)
1,167.80
(+0.56%)
1,423.00
(+0.98%)
1,861.60
(-2.79%)
2,153.00
(-1.62%)
1,171.00
(+1.44%)
2,356.50
(-2.59%)
1,683.30
(-1.96%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
